SIS Ventures

Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.

Dxcover is a clinical-stage liquid biopsy firm that is developing diagnostics for the early diagnosis of numerous malignancies, when treatment has a better possibility of having an influence on outcomes. The business was the first to use infrared spectroscopy of circulating pan-omic indicators to detect and identify cancer. The business has generated compelling clinical data on the diagnosis of Stage I and Stage II malignancies with high accuracy. Dxcover was established in 2016 in Glasgow, Glasgow City by David S Palmer, Holly Butler, and Matthew Baker.

Nebu-Flow is a manufacturer of the next generation of inhaled drugs for patients with respiratory disorders. The company is a developer of the technology control of the droplet size for deep lung deposition by enabling injection-free systemic drug delivery through inhalation routes for cardiovascular and central nerve system disorders. Nebu-Flow is committed to minimizing the environmental impact of activities whilst continuing to create a user-friendly and high-performing Nebuliser.

Carcinotech is revolutionising cancer research by manufacturing 3D-printed micro-tumours using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. Our advanced offering provides a platform for rapid, ethical, and accurate drug screening, pre-clinical, and personalised medicine testing. Carcinotech’s goal is to accelerate drug screening and enable the delivery of more effective cancer treatments to market. Using patient biopsies, tissue engineering, advanced robotic manufacturing, and quality control to produce highly predictive, assay-ready printed tumours at significant throughput. This provides our clients with a “clinical biopsy” quality model, using isolated patient-specific cells and representing donor-specific cancer heterogeneity. Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to each individual suffering from cancer to better their chance of treatment and survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians Carcinotech is changing the face of oncology drug development by working to make this vision a reality.

Good-Loop converts advertising money into funding for social causes in a way that makes online advertising more effective, more rewarding and more ethical. We distribute video ads across our network of quality online publishers. The Good-Loop ad player will never auto-play or interrupt but if you choose to, you can opt-in to watch an advert and then donate 50% of the advertisers' money to your chosen social cause. But Good-Loop isn't just good for the world, it's also good for the advertisers' bottom line. The average completed view rate on YouTube is 30% and on Good-Loop it’s 61% – over double the engagement, for the same price. Good-Loop was part of the Collider Startup Accelerator Program 2017, and winner for their 2017 Demo Day - http://collider.io/

Talking Medicines is revolutionising the pharmaceutical industry and the $30Bn it spend on advertising with its cutting-edge social intelligence platform, PatientMetRx®. By harnessing the power of artificial intelligence (AI) and natural language processing (NLP), the platform transforms unstructured social feedback on patient experience for pharmaceutical companies and their advertising agencies. Using Large Language Models within its advanced AI, clients can answer questions through its Drug-GPT™ of the highly curated patient and Health Care Professional experience to find a single source of truth. This allows companies to deliver a greater return on investment for marketing and ultimately improve health outcomes for patients. With PatientMetRx®, pharmaceutical companies have access to a level of scale and depth of patient insights that was previously impossible, enabling them to make data-driven decisions that drive success.

Trojan Energy support the roll-out of its on-street flat and flush electric vehicle charging points, which aims to solve the issue for vehicle owners who do not have access to off-street parking.

EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections. The company's offerings include developing and advancing novel microbiome-modulating drugs composed of bacterial communities derived directly from the human gastrointestinal tract associated with imbalances of bacteria in the human gut, enabling physicians to prevent and treat debilitating infections and diseases.

Trojan Energy support the roll-out of its on-street flat and flush electric vehicle charging points, which aims to solve the issue for vehicle owners who do not have access to off-street parking.

Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.

Cyan Forensics builds and sells new technologies to help law enforcement, social media companies, and cloud providers to find and block harmful content from paedophiles and terrorists.

Manus Neurodynamica is a triage device to support early diagnostics in Parkinson's disease.

Dxcover is a clinical-stage liquid biopsy firm that is developing diagnostics for the early diagnosis of numerous malignancies, when treatment has a better possibility of having an influence on outcomes. The business was the first to use infrared spectroscopy of circulating pan-omic indicators to detect and identify cancer. The business has generated compelling clinical data on the diagnosis of Stage I and Stage II malignancies with high accuracy. Dxcover was established in 2016 in Glasgow, Glasgow City by David S Palmer, Holly Butler, and Matthew Baker.

Trojan Energy support the roll-out of its on-street flat and flush electric vehicle charging points, which aims to solve the issue for vehicle owners who do not have access to off-street parking.

Cyan Forensics builds and sells new technologies to help law enforcement, social media companies, and cloud providers to find and block harmful content from paedophiles and terrorists.

EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections. The company's offerings include developing and advancing novel microbiome-modulating drugs composed of bacterial communities derived directly from the human gastrointestinal tract associated with imbalances of bacteria in the human gut, enabling physicians to prevent and treat debilitating infections and diseases.

Talking Medicines is revolutionising the pharmaceutical industry and the $30Bn it spend on advertising with its cutting-edge social intelligence platform, PatientMetRx®. By harnessing the power of artificial intelligence (AI) and natural language processing (NLP), the platform transforms unstructured social feedback on patient experience for pharmaceutical companies and their advertising agencies. Using Large Language Models within its advanced AI, clients can answer questions through its Drug-GPT™ of the highly curated patient and Health Care Professional experience to find a single source of truth. This allows companies to deliver a greater return on investment for marketing and ultimately improve health outcomes for patients. With PatientMetRx®, pharmaceutical companies have access to a level of scale and depth of patient insights that was previously impossible, enabling them to make data-driven decisions that drive success.